logo-loader

Milestone Scientific reveals study that shows the cost-effectiveness of its CompuFlo Epidural System

Published: 12:49 20 Apr 2020 EDT

Milestone Scientific Inc (NYSEAMERICAN:MLSS) CEO Len Osser tells Proactive a study was presented at the American Society of Regional Anesthesia and Pain Medicine that validates the cost benefits of Milestone's CompuFlo Epidural System.

What's more, Osser says, is the company recently raised $5M gross to give it more than a one year's runway in the event the coronavirus continues to be widespread. Osser also says a large hospital recently contacted the company, as it was interested to begin trialing its cath check product this week to limit multiple contact between doctors and post-partum patients.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 28 minutes ago